Metformin pharmacokinetics

Metformin pharmacokinetics refers to the absorption, distribution, metabolism, and excretion (ADME) of the biguanide antihyperglycemic agent metformin (StatPearls, 2023). It is not a discrete biological target but a complex pharmacological profile characterized by negligible protein binding and a complete lack of hepatic metabolism. Absorption occurs primarily in the upper small intestine via transporters such as the plasma membrane monoamine transporter (PMAT) and organic cation transporter 3 (OCT3) (PubMed, 2017). Distribution to the liver, its primary site of action, is mediated by OCT1, while renal clearance involves glomerular filtration and active tubular secretion via OCT2, MATE1, and MATE2-K (FDA, 2017). Because metformin is excreted entirely unchanged by the kidneys, its pharmacokinetics are highly sensitive to renal function, and impairment can lead to drug accumulation and the life-threatening risk of lactic acidosis (NIH, 2022).

Other names

Metformin ADMEMetformin dispositionMetformin transportMetformin metabolism

Metformin pharmacokinetics is not a target but a process involving the transport of metformin via Organic Cation Transporters (OCT1, OCT2, OCT3) and Multidrug and Toxin Extrusion proteins (MATE1, MATE2-K) (PubMed, 2011).